Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell carcinoma of the skin.
Squamous Cell Carcinoma of the Skin|Recurrent Skin Cancer
DRUG: Capecitabine
Objective Response Rate (ORR), Response assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), 9 weeks (3 cycles)
Progression-free Survival (PFS) at 1 Year, Proportion of participants with progression-free survival (PFS) at 1 year, as calculated based on Kaplan-Meier estimates., 1 year|Progression-free Survival (PFS) at 2 Years, Proportion of participants with progression-free survival (PFS) at 2 years, as calculated based on Kaplan-Meier estimates., 2 years|Overall Survival (OS) at 1 Year, Proportion of participants with overall survival (OS) at 1 year, as calculated based on Kaplan-Meier estimates., 1 year|Overall Survival (OS) at 2 Years, Proportion of participants with overall survival (OS) at 2 years, as calculated based on Kaplan-Meier estimates., 2 years
Participants are to receive 500 mg/mÂ² of capecitabine orally (PO) twice daily (BID) on days 1 to 14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 2 years.